This has been confirmed in clinical settings, where combined therapy using ipilimumab (CTLA-4 antibody) and nivolumab (PD-1 antibody) has demonstrated greater efficacy than monotherapy in treating advanced melanoma (151). The gene discussed is CTLA4; the disease is melanoma.